Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Marc P Allard-Ratick , Pratik Sandesara , Arshed A Quyyumi , et al Added: 3 years ago
Historically, HDL cholesterol (HDL-C) has been inversely associated with adfverse cardiovascular outcomes such as MI, stroke, and cardiovascular death.1–3 This led to widespread belief that HDL-C, in addition to LDL cholesterol (LDL-C), was a modifiable risk factor for cardiovascular disease. However, efforts to increase HDL-C in high-risk patients with well-controlled LDL-C values have not… View more

Prevention & Chronic Conditions
Author(s): Raif Tawakol Added: 3 years ago
Many patients on statin therapy understandably develop a false sense of security. They enjoy a lowered level of low-desity lipoprotein (LDL) and a risk reduction of some 35%. However, two out of three patients develop a myocardial infarction (MI) while on a statin therapy. Statins often do not increase HDL levels to any substantial degree (except for Rosuvastatin, which increases high-density… View more

Prevention & Chronic Conditions
Author(s): Mohit Gupta , Borut Jug , Matthew J Budoff Added: 3 years ago
Diabetes and Cardiovascular Disease Diabetes has long been recognized as a major risk factor for cardiovascular disease and is widely regarded as a ‘coronary disease equivalent,’1,2 as diabetes and established coronary heart disease indicate a similar absolute risk for cardiovascular death in both men and women.3–5 Cardiovascular complications of diabetes have traditionally been regarded as… View more

Prevention & Chronic Conditions
Author(s): Jean-Claude Tardif , Therese Heinonen Added: 3 years ago
Atherosclerotic cardiovascular disease is the result of a continuous and deleterious interaction between components of the vascular wall and the circulating blood. Circulating lipids and lipoproteins play a significant role in the initiation of fatty streaks and the subsequent progression to complex and vulnerable atherosclerotic plaques. The important role that circulating lipids play in… View more

Prevention & Chronic Conditions
Menopause, Cholesterol and Cardiovascular Disease
Author(s): Heather Currie , Christine Williams Added: 3 years ago
Cardiovascular disease (CVD) is the leading cause of death in both men and women, yet the extent of the problem in women is frequently underestimated and, compared with men, women are less likely to be offered interventions, are less likely to be represented in clinical trials and have a worse prognosis. This article aims to examine the extent of the problem of CVD in women, summarise the… View more

Demographic

Prevention & Chronic Conditions
Secondary Analysis of CANTOS Finds LDL & HDL Predict Residual Risk of Atherosclerotic Events
Author(s): Paul M Ridker Added: 2 years ago
Dr Paul Ridker (Brigham and Women’s Hospital, Boston, US) outlines the findings from a secondary analysis of the CANTOS trial, originally presented at ACC.22 (NCT01327846). CANTOS was a large multinational clinical trial that showed targeting inflammation with canakinumab significantly lowered major cardiovascular events. This secondary analysis was designed to evaluate the influence of lipids… View more

Prevention & Chronic Conditions
Author(s): Sergio Fazio Added: 3 years ago
Introduction The main controversy in the area of lipid management today is related to the usefulness of 'non-statin’ agents to maximize cardiovascular risk reduction in particular patient types, such as those with diabetes and metabolic syndrome. Fibrate drugs, such as gemfibrozil (Lopid) and fenofibrate (TriCor), are undoubtedly the best tools to address the condition characterized by high… View more

Prevention & Chronic Conditions
Author(s): Sergio Fazio Added: 3 years ago
Introduction The main controversy in the area of lipid management today is related to the usefulness of 'non-statinÔÇÖ agents to maximize cardiovascular risk reduction in particular patient types, such as those with diabetes and metabolic syndrome. Fibrate drugs, such as gemfibrozil (Lopid) and fenofibrate (TriCor), are undoubtedly the best tools to address the condition characterized by high… View more

Prevention & Chronic Conditions
Author(s): Sergio Fazio Added: 3 years ago
Current Indications for Statin and Fibrate Therapy The evidence of cardiovascular protection afforded by statins has recently extended beyond patients with hypercholesterolemia. With the publication of several trials,1-7 bold extrapolations of the power of statin therapy in cardiovascular prevention have been offered: statins equally reduce risk in subjects with or without… View more

Prevention & Chronic Conditions
Author(s): Sergio Fazio Added: 3 years ago
Current Indications for Statin and Fibrate Therapy The evidence of cardiovascular protection afforded by statins has recently extended beyond patients with hypercholesterolemia. With the publication of several trials,1-7 bold extrapolations of the power of statin therapy in cardiovascular prevention have been offered: statins equally reduce risk in subjects with or without… View more

Prevention & Chronic Conditions